| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Infection and Immunity, January 2007, p. 429-442, Vol. 75, No. 1
0019-9567/07/$08.00+0 doi:10.1128/IAI.01287-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Microbiology and Molecular Biology, Tufts University, Boston, Massachusetts 02111
Received 10 August 2006/ Returned for modification 25 September 2006/ Accepted 13 October 2006
Yersinia pseudotuberculosis infects many mammals and birds including
humans, livestock, and wild rodents and can be recovered from the lungs
of infected animals. To determine the Y. pseudotuberculosis
factors important for growth during lung infection, we developed an
intranasal model of infection in mice. Following intranasal
inoculation, we monitored both bacterial growth in lungs and
dissemination to systemic tissues. Intranasal inoculation with as few
as 18 CFU of Y. pseudotuberculosis caused a lethal lung
infection in some mice. Over the course of 7 days, wild-type Y.
pseudotuberculosis replicated to nearly 1 x 108
CFU/g of lung in BALB/c mice, induced histopathology in lungs
consistent with pneumonia, but disseminated sporadically to other
tissues. In contrast, a
yopB deletion strain was
attenuated in this model, indicating that translocation of
Yersinia outer proteins (Yops) is essential for virulence.
Additionally, a
yopH null mutant failed to grow to
wild-type levels by 4 days postintranasal inoculation, but deletions of
any other single effector YOP did not attenuate lung colonization 4
days postinfection. Strains with deletions in yopH and any one
of the other known effector yop genes were more attenuated
that the
yopH strain, indicating a unique role for
yopH in lungs. In summary, we have characterized the
progression of a lung infection with an enteric Yersinia
pathogen and shown that YopB and YopH are important in lung
colonization and dissemination. Furthermore, this lung infection model
with Y. pseudotuberculosis can be used to test potential
therapeutics against Yersinia and other gram-negative
infections in
lungs.
Published ahead of print on 30 October 2006.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|